Prosthetic Heart Valves

Published on 05/02/2015 by admin

Filed under Cardiovascular

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2354 times

Chapter 8 Prosthetic Heart Valves

Introduction

Although echocardiography is the imaging modality of choice for cardiac heart valves, it still has significant limitations when imaging prosthetic cardiac valves. These limitations are significant with bioprosthetic valves and are particularly problematic with mechanical valves. The classic limitation is the inability to evaluate mitral regurgitation (MR) from the apical window in patients with mechanical prosthetic valves because of reverberation artifacts and acoustic shadowing. Many of these limitations, particularly while imaging the mitral valve (MV), are overcome by transesophageal imaging; direct imaging from the left atrial side of the valve eliminates these shadowing artifacts, which reside on the ventricular aspect of the valve (Figure 8-1; Video 8-1). Sparse data exist regarding the use of real-time three-dimensional transthoracic echocardiography (RT3DTTE) with prosthetic valves, although in a small series of four patients with endocarditis, vegetations and/or dehiscence not recognized by two-dimensional (2D) TTE were seen.1 Evaluation of prosthetic valves by RT3D transesophageal echocardiography (TEE) has been extensively reviewed.2,3 In one study, RT3DTEE has been shown to be particularly accurate for diagnosing all types of prosthetic valve pathology compared with direct surgical inspection.4 However, MV visualization, particularly valve leaflet visualization, was far superior to that of aortic or tricuspid valves. Also in this study, most of the valves were free of disease and, in fact, had recently been placed. Despite being a study of 87 patients, fewer than 40 had prosthetic valves, and the number who had metallic prosthetic valves is not clear from the report.

A notable advantage of RT3DTEE compared with 2DTEE for all mechanical valves in the mitral position is the ability to visualize the entire valve in one full-volume or 3D zoom capture compared with visualization of only a single thin slice by 2D (Figures 8-1 to 8-6; Videos 8-1 to 8-6). Besides live 3D imaging, RT3DTEE has the ability to acquire a 3D volume that can then be cropped and rotated to reveal pathology such as leaflet immobility, thrombi or vegetations, dehiscence, or, with the addition of 3D color, even small perivalvular leaks (see Figure 8-4 and Video 8-4). Details of the valve, such as the sewing ring, the individual stitches, the struts, and the entire leaflet motion are well visualized by RT3DTEE (see Figure 8-6 and Video 8-6). Again, such visualization is much less frequently seen in valves in either the aortic or tricuspid position.

Abnormal Pathology with Mechanical Valves

Visualization of masses or the pannus on mechanical valves by RT3DTEE has not been rigorously studied because such problems are relatively uncommon. Only case reports exist of pannus formation on bileaflet mechanical valves in the mitral position evaluated by RT3DTEE, but in one published case, the pannus was identified by RT3DTEE and not seen at all by 2DTEE.5 Thrombus formation can be more precisely evaluated by RT3DTEE than by 2DTEE; in fact, this has confirmed our observation of the ability of RT3DTEE to appreciate that thrombi are larger and more numerous than thrombi detected by 2DTEE.6,7

Mitral Prosthetic Dehiscence

RT3DTEE provides additional information in patients with a postoperative MV dehiscence and therefore may help plan an optimal corrective intervention. Kronzon and colleagues,9 in a series of 18 patients with dehisced MVs, 10 after replacement and 8 after repair, used RT3DTEE for echocardiographic evaluation. In all cases, the position of the valve dehiscence was more extensively characterized by RT3DTEE than with 2DTEE, and the position of dehiscence was confirmed to be correct in 10 of the patients by surgical findings. The presence of valve dehiscence was correctly diagnosed by 2DTEE in 17 of the 18 patients, but the type of valve ring or the position of the valve dehiscence could not be characterized in any case. Ten of the patients had posterior dehiscence, and four had lateral dehiscence. These positions were believed to be the most prominent because (1) the posterior annulus is the most difficult portion of the valve ring to reach surgically and (2) surgeons attempt to avoid the circumflex coronary artery.9

Guidance of Percutaneous Valve Placement

TEE is the standard for guiding percutaneous transcatheter aortic valve implantation. Data regarding the use of RT3DTEE for this particular procedure are limited, although it is routinely performed.10 Several potential advantages exist for RT3DTEE in this setting. The third dimension allows (1) more accurate assessment of the aortic annulus, the left ventricular outflow tract, and the aortic root size and shape; (2) measurement of the distance between the annulus and the left main coronary artery ostium; and 3) seating of the percutaneous valve while viewing the aortic valve en face and visualizing the valve leaflets and the tissue surrounding the prosthetic annulus.11 This en face view is critically important for placement of the prosthetic valve to avoid postprocedure perivavluar regurgitation. RT3DTEE and biplane imaging also assist with the perioperative monitoring of all procedural aspects, including advancements of guidewires into the aortic valve and the placement of pigtail catheters in the sinus of Valsalva and the left ventricle, as well as balloon valvuloplasty or valve deployment. Ultimately, 2DTEE and RT3DTEE should be used as complementary imaging modalities to assess the satisfactory positioning and function of the implanted valve.

Reports of small series of transcatheter mitral valve-in-valve implantations have appeared in the literature. RT3DTEE has also been routinely used for this purpose.12 Although this procedure is currently not available in the United States, RT3DTEE will be a mainstay for deployment of mitral valve-in-valve devices when they do become available.

Guidance of Percutaneous Valve Repair

3D echocardiography has been used for guidance during percutaneous mitral valvuloplasty and has been shown to be a suitable technique for monitoring its efficacy and complications.13 RT3DTEE may become the gold standard in describing the morphology of commissures as a good predictor of outcome after percutaneous balloon mitral valvuloplasty.14 Balloon valvuloplasty in patients with rheumatic MV stenosis was the first percutaneous procedure used in the management of patients with MV disease. RT3DTEE not only guides the transseptal approach, it also improves the spatial orientation of the catheter system in reference to the MV and permits immediate inspection of the MV after the valvuloplasty.15

Percutaneous approaches to the management of MR continue to be developed. A large number of percutaneous devices to manage mitral dysfunction have been directed at reduction of the annulus (e.g., Viacor [Viacor, Inc., Wilmington, MA], Monarch coronary sinus retracting stent [Edwards Lifesciences, Irvine, CA]), stabilization of the valve leaflet motion (e.g., MitraClip, Evalve [Abbott Vascular, Abbott Park, IL]), or reduction of leaflet restriction (Coapys [Myocor, Maple Grove, MN], subvalvular stabilization, cutting secondary chords). Recent evidence supports the utility of the simple edge-to-edge technique (MitraClip) in those not amenable to conventional surgical repairs. Based on the initial performance of edge-to-edge repair by catheter-based technology, percutaneous edge-to-edge repair was performed in the randomized, phase II Pivotal Study of a Percutaneous Mitral Valve Repair System (EVEREST II). The results of that trial suggest that percutaneous repair with the MitraClip system can be accomplished with low rates of morbidity and mortality and with acute MR reduction to less than 2+ in the majority of selected patients. This technology may soon become a less invasive alternative to surgical mitral valve repair in the future.16,17

TEE not only confirms the diagnosis of MR and describes MV morphology before a percutaneous MV procedure but also has been shown to be critically important in guiding the edge-to-edge repair. In brief, with the patient under general anesthesia—and with the aid of RT3DTEE, biplane viewing, and fluoroscopy—a guidewire, followed by an introducer, is advanced into the right atrium via the right femoral vein. After transseptal puncture (high posterior approach as confirmed by TEE) a 24-Fr guiding catheter is advanced into the left atrium. From this perspective, the externally controlled MitraClip delivery system is steered over the mitral orifice with continued TEE guidance. Within the left atrium, the mitral clip is oriented perpendicular to the long axis of the MV leaflet edges at the origin of the mitral regurgitation jet. In our experience, this step benefits most from the added third dimension. The clip is then advanced into the left ventricle with placement of the clip arms below the mitral leaflets. Grasping of the mitral leaflets is then performed by retraction of the clip delivery system. After confirmation of appropriate leaflet insertion into the clip and adequate reduction in MR severity by TEE, the clip is deployed. After deployment, the severity of the MR is again reassessed by both 2DTEE and 3DTEE with and without color flow Doppler.

Most of the potential complications of this percutaneous approach to MR can be monitored and diagnosed with TEE. The complications include (1) potential of aortic root puncture during atrial septal perforation (right atrium to aortic fistula), (2) right or left atrial puncture by the deployment device (cardiac tamponade), (3) increased MR during device deployment, (4) development of mitral stenosis, (5) creation of a large atrial septal defect, (6) device embolization, and (7) unsuccessful repair.

Case Studies

Case 3 (Figures 8-14 to 8-21; Videos 8-13 to 8-16)

Left ventricular outflow tract mass: A bioprosthetic valve was present in the aortic position. TTE suggested a vegetation on the aortic valve. By TEE, a mass was seen prolapsing into the left ventricular outflow tract and was confirmed by RT3DTEE. Although endocarditis could not be excluded by TEE, it was believed to possibly represent primary valve failure. Subsequent cultures did not grow any organisms. Because of aortic regurgitation, the valve was subsequently replaced with another bioprosthetic valve.

Case 5 (Figures 8-24 to 8-30; Videos 8-19 to 8-22)

Vegetation on a prosthetic aortic valve: TEE was performed on this patient, who had blood cultures positive for Candida tropicalis. A vegetation was seen on the prosthetic St. Jude aortic valve.

Case 6 (Figures 8-31 to 8-35; Videos 8-23 to 8-26)

Fungal endocarditis of a bioprosthetic valve in the mitral position: Six months after implantation of a porcine bioprosthetic valve in the mitral position and coronary artery bypass grafting, this 74-year-old female patient was admitted with fever, symptoms of acute heart failure, and multiple episodes of syncope. TEE revealed near-complete stenosis of her stented bioprosthesis due to massive fungal endocarditis (Exserohilum spp.).

image

Figure 8-32 Three-dimensional transesophageal echocardiography en face view of the completely overgrown bioprosthetic valve in the mitral position shown in Figure 8-31. Note the severely stenosed mitral valve bioprosthesis with an effective orifice area of 0.3 cm2 (see Video 8-24).

image

Figure 8-34 The completely overgrown bioprosthetic valve shown in Figure 8-31 as it was excised from the mitral position. Note that the fungal process has resulted in a near-complete obliteration of the bioprosthesis.

image

Figure 8-35 Postoperative three-dimensional (3D) en face image in the patient shown in Figure 8-31 obtained with live 3D acquisition demonstrating the replaced bioprosthesis in the mitral position (see Video 8-26).

Case 8 (Figures 8-38 to 8-42; Videos 8-30 to 8-34)

A 64-year-old man who underwent coronary artery bypass grafting and St. Jude mitral valve replacement in 1998: The patient developed Streptococcus constellatus endocarditis and underwent repeat MV replacement in January 2008 with a CarboMedics (Sorin Group, Milan, Italy) mechanical valve. After that surgery, the patient never regained his previous state of health and had progressive loss of strength as well as increasing shortness of breath at rest and with mild activity. He was ultimately found to have persistent anemia; blood cultures were positive for methicillin-resistant Staphylococcus epidermidis on four occasions, and he was placed on appropriate antibiotics. TTE showed severe MR and a rocking MV prosthesis. Intraoperative TEE confirmed anterior dehiscence of the mechanical bileaflet tilting-disk valve in the mitral position along with rocking motion. The extent and location of the dehiscence are easily appreciated on the RT3DTEE en face view, but the mid-esophageal, two-chamber view with the multiplane angle at 90 degrees does not reveal the dehiscence.

image

Figure 8-40 Two-dimensional transesophageal echocardiography two-chamber view of the same dehisced tilting-disk prosthesis in the mitral position shown in Figure 8-39. Note that the dehiscence is not necessarily being detected at this orientation of the multiplane angle (i.e., 96 degrees). However, the moving image demonstrates the rocking motion of the mechanical valve (see Video 8-32).

image

Figure 8-41 Zoomed real-time three-dimensional transesophageal echocardiography en face image of the anteriorly dehisced tilting-disk prosthesis shown in Figure 8-39. Note that the dehiscence extends at the entire anterior aspect of the valve (arrows) (see Video 8-33). AV, aortic valve.

References

1 Kort S. Real-time 3-dimensional echocardiography for prosthetic valve endocarditis: Initial experience. J Am Soc Echocardiogr. 2006;19:130–139.

2 Tsang W, Weinert L, Kronzon I, Lang RM. Three-dimensional echocardiography in the assessment of prosthetic valves. Rev Esp Cardiol. 2011;64:1–7.

3 Chapman CB, Rahko PS. Three-dimensional echocardiography and mitral valve disease. Curr Cardiol Rep. 2010;12:243–249.

4 Sugeng L, Shernan SK, Weinert L, et al. Real-time three-dimensional transesophageal echocardiography in valve disease: Comparison with surgical findings and evaluation of prosthetic valves. J Am Soc Echocardiogr. 2008;21:1347–1354.

5 Ozkan M, Gunduz S, Yildiz M, Duran NE. Diagnosis of the prosthetic heart valve pannus formation with real-time three-dimensional transoesophageal echocardiography. Eur J Echocardiogr. 2010;11:E17.

6 Faletra FF, Moschovitis G, Auricchio A. Visualisation of thrombus formation on prosthetic valve by real-time three-dimensional transoesophageal echocardiography. Heart. 2009;95:482.

7 Paul B, Minocha A. Thrombosis of a bileaflet prosthetic mitral valve: A real-time three-dimensional transesophageal echocardiography perspective. Int J Cardiovasc Imag. 2010;26:367–368.

8 Singh P, Manda J, Hsiung MC, et al. Live/real time three-dimensional transesophageal echocardiographic evaluation of mitral and aortic valve prosthetic paravalvular regurgitation. Echocardiography. 2009;26:980–987.

9 Kronzon I, Sugeng L, Perk G, et al. Real-time 3-dimensional transesophageal echocardiography in the evaluation of post-operative mitral annuloplasty ring and prosthetic valve dehiscence. J Am Coll Cardiol. 2009;53:1543–1547.

10 Marcos-Alberca P, Zamorano JL, Sanchez T, et al. Intraoperative monitoring with transesophageal real-time three-dimensional echocardiography during transapical prosthetic aortic valve implantation. Rev Esp Cardiol. 2010;63:352–356.

11 Zamorano JL, Badano LP, Bruce C, et al. EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. J Am Soc Echocardiogr. 2011;24:937–965.

12 Cheung AW, Gurvitch R, Ye J, et al. Transcatheter transapical mitral valve-in-valve implantations for a failed bioprosthesis: a case series. J Thorac Cardiovasc Surg. 2011;141:711–715.

13 Dobarro D, Gomez-Rubin MC, Lopez-Fernandez T, et al. Real time three-dimensional transesophageal echocardiography for guiding percutaneous mitral valvuloplasty. Echocardiography. 2009;26:746–748.

14 Fatkin D, Roy P, Morgan JJ, Feneley MP. Percutaneous balloon mitral valvotomy with the Inoue single-balloon catheter: Commissural morphology as a determinant of outcome. J Am Coll Cardiol. 1993;21:390–397.

15 Perk G, Lang RM, Garcia-Fernandez MA, et al. Use of real time three-dimensional transesophageal echocardiography in intracardiac catheter based interventions. J Am Soc Echocardiogr. 2009;22:865–882.

16 Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: Safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009;54:686–694.

17 Mauri L, Garg P, Massaro JM, et al. The EVEREST II Trial: Design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J. 2010;160:23–29.